Ladenburg initiated coverage of Kala Pharmaceuticals (KALA) with a Buy rating and $12 price target The company is targeting a $1B-plus orphan ophthalmology market, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA:
- Promising Developments and Market Potential for Kala Pharmaceuticals’ KPI-012 Amidst Clinical and Regulatory Challenges
- Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial
- Kala completes patient enrollment for CHASE Phase 2 clinical trial
- Kala Pharmaceuticals assumed with an Outperform at Oppenheimer
- Kala Pharmaceuticals price target lowered to $12 from $15 at H.C. Wainwright